Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
If dose precision matters to your research protocol, the calculator isn't optional
There is more sun
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Szary syndrome)
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed by the MHRA or EMA for use in the UK
But with this progress comes responsibility ensuring that the delivery of these breakthrough therapies aligns with the sustainability imperatives of the future
Designing appropriate drugs according to the genetic background and disease characteristics of patients can achieve precision treatment and further improve the treatment effect
US$ 27.50
US$ 22.49
US$ 21.71
US$ 26.15
US$ 28.22
US$ 20.03
